Sugi Predict

Sugi Predict / Compounds / SCHEMBL47579

SCHEMBL47579

SCHEMBL47579

CC(C)(C)c1cc(Cl)cc(C(C)(C)C)c1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.64
▸ CA1 P00915 2/20 0.64
▸ ALDH1A1 P00352 7/20 0.61
▸ SMN1; SMN2 Q16637 6/20 0.61
▸ POLB P06746 1/20 0.61
▸ TYR P14679 1/20 0.61
▸ ALOX15 P16050 4/20 0.54
▸ MAPT P10636 4/20 0.54
▸ HPN P05981 1/20 0.54
▸ SIRT5 Q9NXA8 1/20 0.54
▸ CYP2C9 P11712 4/20 0.48
▸ CYP2C19 P33261 4/20 0.48
▸ HIF1A Q16665 4/20 0.48
▸ TP53 P04637 3/20 0.48
▸ GAA P10253 4/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ TSHR P16473 4/20 0.48
▸ NPSR1 Q6W5P4 4/20 0.48
▸ LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11779667 0.88 ALDH1A1 (0.56) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL4879678 0.88 CA2 (0.50) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL23079288 0.88 CA2 (0.50) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL7034392 0.86 CYP2C9 (0.63) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL1107957 0.85 CA2 (0.48) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL5085724 0.84 IGF1R (0.47) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL11649954 0.83 SMN1; SMN2 (0.55) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL8897075 0.83 HSPA5 (0.63) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL11722271 0.81 HSPA5 (0.47) CA2CA1ALDH1A1SMN1; SMN2POLB
SCHEMBL1170584 0.81 HSPA5 (0.53) CA2CA1ALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037418-A Oil-resistant weather-resistant cable sheath material and preparation method thereof 浙江千诺新材料科技有限公司 2026-05-15 — — CN claimed
CN-122037481-A Aging-resistant long-acting antibacterial plastic bottle and preparation method thereof 佛山市恒信功成塑料有限公司 2026-05-15 — — CN claimed
CN-120000698-A Use of stevia extract 上海维丘康敬生物科技有限公司 2025-05-16 — — CN claimed
CN-119859484-A Adhesive for improving dispersion uniformity of self-heating powder and preparation method thereof 浙江珍视明眼健康产业有限公司 2025-04-22 — — CN claimed
CN-119592234-A High-adhesion silicon-containing adhesive and preparation method thereof 黄河源股份公司 2025-03-11 — — CN claimed
US-11224241-B2 Methods and compositions for affecting the flavor and aroma profile of consumables IMPOSSIBLE FOODS INC. (US) 2022-01-18 — — US claimed
US-11219232-B2 Methods and compositions for affecting the flavor and aroma profile of consumables IMPOSSIBLE FOODS INC. (US) 2022-01-11 — — US claimed
US-20200061070-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF PTC THERAPEUTICS MP, INC. 2020-02-27 — — US claimed
US-10327464-B2 Methods and compositions for affecting the flavor and aroma profile of consumables IMPOSSIBLE FOODS INC. (US) 2019-06-25 — — US claimed
US-10314325-B2 Methods and compositions for affecting the flavor and aroma profile of consumables IMPOSSIBLE FOODS INC. (US) 2019-06-11 — — US claimed
EP-3053992-A1 Biodiesel LANXESS Deutschland GmbH (DE) 2016-08-10 — — EP claimed
US-20100028389-A1 HYDROMORPHONE THERAPY MALLINCKRODT LLC 2010-02-04 — — US claimed
WO-2001068740-A1 CHARGE TRANSPORT MATERIALS AVECIA LIMITED (GB) 2001-09-20 — — WO claimed
US-12637465-B2 Pharmaceutically acceptable salts of sepiapterin PTC THERAPEUTICS MP, INC. (US) 2026-05-26 — — US disclosed
US-12629366-B2 Pharmaceutical compositions comprising sorbitan esters ALKERMES PHARMA IRELAND LIMITED (IE) 2026-05-19 — — US disclosed
CN-122037481-A Aging-resistant long-acting antibacterial plastic bottle and preparation method thereof 佛山市恒信功成塑料有限公司 2026-05-15 — — CN disclosed
US-5324280-A Osmotic dosage system for delivering a formulation comprising liquid carrier and drug ALZA CORPORATION (US) 1994-06-28 — — US disclosed
EP-0523172-A1 OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY. ALZA CORP (US) 1993-01-20 — — EP disclosed
WO-1991015196-A1 OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY ALZA CORPORATION (US) 1991-10-17 — — WO disclosed
US-4525362-A Mosquito development inhibitor employing substituted phenols CLAUSE (S.A.) (FR) 1985-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629366-B2 Pharmaceutical compositions comprising sorbitan esters FABP7, SLC6A4, SLC6A3 CA2 1528/4885CA1 2817/4885ALDH1A1 960/4885
US-12637465-B2 Pharmaceutically acceptable salts of sepiapterin PAH, QDPR, SPR CA2 1876/4885CA1 2411/4885ALDH1A1 1262/4885
US-20200061070-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF SPR, PCSK9, SLC6A7 CA2 3025/4885CA1 3845/4885ALDH1A1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.